The development of concise grading schemes for diffuse gliomas with proven relevance to tumor behavior and susceptibility to therapy is important for clinical decision making. At present, there is unacceptably large interobserver discrepancy in the application of the current World Health Organization (WHO) criteria for accrual of patients in trials for patients with gliomas. Because of a lack of relevant studies, the WHO guidelines for grading are not yet as clear aswould be desirable. The development of well-defined grading schemes consisting of features with low interobserver scoring variability and prognostic or predictive relevance is needed. Although interobserver concordance can be tested in retrospective studies, the prognostic or predictive qualities of histological parameters can only be tested in prospective studies. Only evidence-based histopathology will retain its critical role in the diagnosis and treatment of diffuse gliomas.

Astrocytoma, Glioblastoma, Glioma, Grading, Histopathology, Oligodendroglioma, astrocytoma, brain tumor, cancer combination chemotherapy, cancer radiotherapy, cancer survival, cell proliferation, clinical trial (topic), diagnostic accuracy, diagnostic test, diagnostic test accuracy study, disease severity, ependymoma, glioblastoma, glioma, histopathology, human, immunohistochemistry, interrater reliability, lomustine, neuroimaging, neuropathology, nuclear magnetic resonance imaging, oligodendroglioma, overall survival, perfusion weighted imaging, pilocytic astrocytoma, practice guideline, priority journal, procarbazine, prognosis, prospective study, proton nuclear magnetic resonance, review, subependymoma, tumor localization, vincristine, world health organization,
Journal of Neuropathology and Experimental Neurology
Erasmus MC: University Medical Center Rotterdam

Kros, J.M. (2011). Grading of gliomas: The road from eminence to evidence. Journal of Neuropathology and Experimental Neurology (Vol. 70, pp. 101–109). doi:10.1097/NEN.0b013e31820681aa